

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/70, G01N 33/53 C12N 7/00, 15/00, 1/20 G01N 33/566	A1	(11) International Publication Number: WO 91/17271 (43) International Publication Date: 14 November 1991 (14.11.91)
(21) International Application Number: PCT/US91/02989 (22) International Filing Date: 1 May 1991 (01.05.91) (30) Priority data: 517,659 1 May 1990 (01.05.90) US (60) Parent Application or Grant (63) Related by Continuation US 517,659 (CIP) Filed on 1 May 1990 (01.05.90) (71) Applicant (for all designated States except US): AFFYMAX TECHNOLOGIES N.V. [NL/NL]; De Ruyderkade 62, Curaçao (AN). (72) Inventors; and (75) Inventors/Applicants (for US only): DOWER, William, J. [US/US]; 761 Partridge Avenue, Menlo Park, CA 94025 (US). CWIRLA, Steven, E. [US/US]; 765 San Antonio Road, #64, Palo Alto, CA 94303 (US).		(74) Agent: SMITH, William, M.; Townsend and Townsend, One Market Plaza, 2000 Steuart Tower, San Francisco, CA 94105 (US). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (Euro- pean patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report.</i>
(54) Title: RECOMBINANT LIBRARY SCREENING METHODS		
(57) Abstract Nucleotide sequences encoding proteins of interest are isolated from DNA libraries using bacteriophage to link the protein to the sequence which encodes it. DNA libraries are prepared from cells encoding the protein of interest and inserted into or adjacent to a coat protein of a bacteriophage vector, or into a sequence encoding a protein which may be linked by means of a ligand to a phage coat protein. By employing affinity purification techniques the phage particles containing sequences encoding the desired protein may be selected and the desired nucleotide sequences obtained therefrom. Thus, for example, novel proteins such as monoclonal antibodies may be produced and conventional hybridoma technology avoided.		

"RF" DNA of filamentous phage), and to clone the separate libraries in different versions of the vector containing different cloning sites and different selectable markers (Amp^R and Tet^R, for example). The sequences from the separate libraries are joined so that a sequence of interest and a corresponding selectable marker from each library resides in each single phage genome. Application of double selection will enrich for those hosts harboring the combined phage genomes. Alternatively, in accordance

with the present invention antibody light and heavy chains can be expressed from separate plasmids.

In other embodiments the V region domains of heavy and light chains can be expressed on the same polypeptide, joined by a flexible linker to form a single-chain Fv fragment, which gene sequences can then be cloned into the desired vector. As generally described in McCafferty et al., Nature 348:552-554 (Dec. 6, 1990), complete antibody V domains of an anti-lysozyme antibody, joined by a flexible (Gly₄-Ser)₃ linker and cloned into an fd phage vector fdCAT1 at the N-terminal region of the gene III protein, produce an antibody-gene III fusion which is detectable in the recombinant phage. The recombinant phage can be affinity-purified over a lysozyme-Sepharose® column and subsequently further enriched by propagating the isolated phage.

In yet another approach, one or both of the antibody light and heavy chains (or the V regions thereof) can be expressed by a phagemid, that is, a vector which combines features of plasmids, such as a bacterial ColE1 origin of replication, and filamentous bacteriophages, such as the major intergenic region. Phagemids are discussed generally in Sambrooke et al., supra, at pages 4.17-4.19 and 4.44-4.50, which are incorporated herein by reference. The vector can be maintained as a small plasmid vector by selection, or the plasmid can be efficiently packaged into virions, or phagemid particles, by infection with helper phage, such

as M13K07. As described generally in Bass et al.,
Proteins 8:309-314 (1990), controlling the copy number of
gene III fusion proteins which are produced in a mixture
of both wild-type gene III and a gene III fusion protein
on phagemid particles permits proper folding of a fusion
protein while allowing efficient panning of large epitope
libraries. Thus, it is possible to sort phagemid
particles whose peptides are of relatively high affinity,
with binding constants in the micromolar to nanomolar
range.

As mentioned, the vectors may be engineered to
efficiently clone the library amplification products.
For example, oligonucleotides may be used to introduce
the asymmetric restriction sites, a ribosome binding site
at an optimal distance for expression of the cloned
sequence, and cloning sites for the library amplification
products.

In certain embodiments of the invention at
least one of the library-encoded protein chains is cloned
into a vector so as to be expressed fused to a tag
protein. As used herein, a "tag" protein is meant to
refer to a protein which has a specific binding affinity
for a peptide or protein ligand. For example, the tag
protein should have specificity for a peptide or protein
ligand of at least about 3 to about 100 or more amino
acids, preferably with an affinity exceeding at least
about 10^{-7} to 10^{-8} M, and more preferably equal to or
greater than about 10^{-9} M. A tag protein with more than
one binding site for the tag ligand peptide provides a
resulting increase in avidity, which greatly decreases
the dissociation rate and somewhat relaxes the
requirement for affinity at each site (the affinity of
each binding site may then be as low as about 10^{-6} M).
The tag protein should be preferably less than about
100kD but may be more, and should be of a composition
such that its fusion with the protein of interest, e.g.,
the N-terminus of the tag with the C-terminus of an